Brief Report: Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study Amivantamab, an EGFR–MET bispecific antibody, is approved for multiple indications in EGFR-mutated advanced non-small cell lung cancer (NSCLC) as mono…

Excited to share our #SKIPPirr study was just published. Great job everyone involved in this study. #EGFR #NSCLC #PatientFocus #MyCompany
www.sciencedirect.com/science/arti...